Latest in Clinical Trials (Phases I–IV)

613 words

Chiesi Global Rare Diseases Supports Continued Generation of Real-World and Scientific Evidence in Epidermolysis Bullosa (EB), Including New Data Presented at 2026 PeDRA Annual Conference

-- New mechanistic research and clinician-reported real-world experience adds to the evolving evidence base for birch triterpenes in EB -- -- Chiesi proudly marks EB Awareness Week (October 25–31) with continued research, awareness and support for the EB community -- Details of the three presentations…

stocktitan.net
844 words

EyePoint LUCIA Phase 3 trial misses primary endpoint

J-Star Holding Co., Ltd. Advances U.S. Drone Manufacturing Initiative; Negotiates Acquisition of Facility in the Greater Houston Area Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset Knox and Palantir Partner to Further Accelerate…

Clinical Trials (Phases I–IV)

Design, endpoints, enrollment, interim reads, and post‑market surveillance.

  • 4 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.